Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Investing.com - Dare Bioscience reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Dare Bioscience announced earnings per share of $-0.0800 on revenue of $7.96M. Analysts polled by Investing.com EPS of $-0.1175 on revenue of $3.98M.
Dare Bioscience 's are down 53.92% and is trading at $0.9190 , still down 63.39% from its 52 week high of $2.51 set on Wednesday, December 8, 2021.
Dare Bioscience follows other major Healthcare sector earnings this month
Dare Bioscience's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar